Status:
COMPLETED
Crestor Versus Placebo in Subjects With Heart Failure
Lead Sponsor:
AstraZeneca
Conditions:
Heart Failure
Eligibility:
All Genders
60+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to investigate if rosuvastatin, added on top of all other medicines prescribed to subjects with symptomatic systolic heart failure, reduces the combined endpoint of cardiov...
Eligibility Criteria
Inclusion
- Chronic symptomatic systolic heart failure of ischaemic aetiology as judged by the investigator, optimal therapy for chronic symptomatic systolic heart failure according to the investigator
Exclusion
- Acute myocardial infarction within 6 months before randomization
- Treatment with any statin or other lipid lowering drug; or a medical condition that in the opinion of the investigator requires treatment with a statin or other lipid lowering drug
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
5013 Patients enrolled
Trial Details
Trial ID
NCT00206310
Start Date
September 1 2003
End Date
July 1 2007
Last Update
November 19 2010
Active Locations (375)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalst, Belgium
2
Research Site
Bouge, Belgium
3
Research Site
Bruges, Belgium
4
Research Site
Brussels, Belgium